Gerresheimer (GXI) Given a €86.00 Price Target by Deutsche Bank Analysts
A number of other equities research analysts have also commented on the stock. Commerzbank set a €68.00 ($79.07) price target on shares of Gerresheimer and gave the company a neutral rating in a report on Thursday, June 21st. Kepler Capital Markets set a €65.00 ($75.58) price target on shares of Gerresheimer and gave the company a sell rating in a report on Thursday, July 12th. HSBC set a €67.00 ($77.91) price target on shares of Gerresheimer and gave the company a neutral rating in a report on Monday, July 16th. DZ Bank reiterated a buy rating on shares of Gerresheimer in a report on Thursday, July 12th. Finally, Hauck & Aufhaeuser set a €52.50 ($61.05) price target on shares of Gerresheimer and gave the company a sell rating in a report on Monday, July 2nd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. The company has an average rating of Hold and an average target price of €72.67 ($84.50).
GXI opened at €77.25 ($89.83) on Friday. Gerresheimer has a twelve month low of €59.97 ($69.73) and a twelve month high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Featured Story: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.